Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Thirteen Patent Applications Related to RNAi

Premium
Title: Methods and Compositions for Controlling Efficacy of RNA Silencing
 
Number: 7,459,547
 
Filed: June 2, 2004
 
Lead Inventor: Phillip Zamore, University of Massachusetts Medical School (Intradigm)
 
“Based at least in part on an understanding of the mechanisms by which small RNAs mediate RNA silencing in plants, rules have been established for determining, for example, the degree of complementarity required between an RNAi-mediating agent and its target, i.e., whether mismatches are tolerated, the number of mismatches tolerated, the effect of the position of the mismatches, etc.,” the patent’s abstract states. “Such rules are useful, in particular, in the design of improved RNAi-mediating agents which allow for more exact control of the efficacy of RNA silencing.”
 

 
Title: Nucleic Acid Compounds for Inhibiting VEGF Gene Expression and Uses Thereof
 
Number: 20080286866
 
Filed: Feb. 28, 2008
 
Lead Inventor: Steven Quay, Nastech Pharmaceutical (MDRNA)
 
The invention, the patent application’s abstract states, comprises “meroduplex ribonucleic acid molecules capable of decreasing or silencing VEGFA, VEGFB, VEGFC, FIGF, or PGF gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a VEGF mRNA. In addition, the meroduplex may have at least one 5-methyluridine, locked nucleic acid, 2'-O-methyl, or optionally other modifications, and any combination thereof,” the abstract notes. “Also provided are methods of decreasing expression of a VEGF gene in a cell or in a subject to treat a VEGF-related disease.”
 

 
Title: Oligonucleotides and Methods of Use Thereof for Treatment of Alopecia, Acute Renal Failure, and Other Diseases
 
Number: 20080287382
 
Filed: Jan. 11, 2008
 
Lead Inventor: Elena Feinstein, Quark Pharmaceuticals
 
“The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene,” the patent application’s abstract states. “The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier.”
 
The abstract adds that the invention also “contemplates a method of treating a patient suffering from alopecia or acute renal failure or other diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The alopecia may be induced by chemotherapy or radiotherapy, and the patient may be suffering from cancer, in particular breast cancer.”
 

 
Title: Nucleic Acid Compounds for Inhibiting ERBB Gene Expression and Uses Thereof
 
Number: 20080287383
 
Filed: Feb. 28, 2008
 
Lead Inventor: Steven Quay, Nastech Pharmaceutical (MDRNA)
 
According to the patent application’s abstract, the invention comprises “meroduplex ribonucleic acid molecules capable of decreasing or silencing ERBB gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an ERBB mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid, or optionally other modifications, and any combination thereof.”
 
The abstract adds that the application further claims “methods of decreasing expression of an ERBB gene in a cell or in a subject to treat an ERBB-related disease.”
 

 
Title: Inhibitor Oligonucleotides and Their Use for Specific Repression of a Gene
 
Number: 20080287385
 
Filed: Feb. 28, 2008
 
Lead Inventor: Annick Harel-Bellan, Centre National de la Recherche Scientifique
 
The patent application, its abstract states, claims “a double-strand oligonucleotide including two complementary oligonucleotide sequences forming a hybrid, each including at one of their 3' or 5' ends one to five unpaired nucleotides forming single-strand ends extending beyond the hybrid.”
 
The abstract adds that “one of the oligonucleotide sequences [is] substantially complementary to a target sequence belonging to a DNA or RNA molecule” for a gene coding an angiogenic factor.
 

 
Title: Oligonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases
 
Number: 20080287386
 
Filed: Feb. 28, 2008
 
Lead Inventor: Orna Mor, Quark Pharmaceuticals
 
“The invention,” the patent application’s abstract states, “relates to a double-stranded compound, preferably an oligoribonucleotide, [that] down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound … a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The … invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney, and liver fibrosis or ocular scarring [by] administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide.”
 

 
Title: shRNA Materials and Methods of Using Same for Inhibition of DKK-1
 
Number: 20080293053
 
Filed: Dec. 28, 2007
 
Lead Inventor: Evan Keller, University of Michigan
 
The patent application, its abstract states, claims “methods and compositions for the treatment of soft tissue cancer. … More specifically, the invention demonstrates that inhibiting or otherwise decreasing the activity of DKK-1 using shRNA or siRNA molecules will be effective at reducing the cancer phenotype of prostate cancer cells.”
 

 
Title: Nucleic Acid Compounds for Inhibiting AKT Gene Expression and Uses Thereof
 
Number: 20080293136
 
Filed: Feb. 28, 2008
 
Lead Inventor: Steven Quay, Nastech Pharmaceutical (MDRNA)
 
The invention, the patent application’s abstract states, comprises “meroduplex ribonucleic acid molecules capable of decreasing or silencing AKT gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to an AKT mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside replaced with a locked nucleic acid or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of an AKT gene in a cell or in a subject to treat an AKT-related disease.”
 

 
Title: Multiple shRNA Expression Vectors and Methods of Construction
 
Number: 20080293142
 
Filed: April 18, 2008
 
Lead Inventor: Lin Liu, Oklahoma State University
 
The patent application, its abstract states, claims “a research or therapeutic tool for RNA interference [that] is a single vector [expressing] multiple short hairpin RNA sequences.”
 

 
Title: siRNA Targeting Casitas B Cell Lymphoma-B
 
Number: 20080293593
 
Filed: July 23, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CBL-B.”
 

 
Title: siRNA Targeting Protein Tyrosine Phosphatase-1B
 
Number: 20080293595
 
Filed: July 24, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PTP1B.”
 

 
Title: Novel Tandem siRNAs
 
Number: 20080293655
 
Filed: Feb. 8, 2007
 
Lead Inventor: Huseyin Aygun, BioSpring
 
The invention, the patent application’s abstract states, “provides novel molecules, compositions, methods, and uses for treating microvascular disorders, eye diseases, and respiratory conditions based upon inhibition of two or more target genes.”
 

 
Title: Fc Gamma RIIA-Specific Nucleic Acid Interference
 
Number: 20080293659
 
Filed: March 25, 2008
 
Lead Inventor: Diana Beardsley, Yale University School of Medicine
 
The invention, according to the patent application’s abstract, “provides methods and compositions for attenuating expression of Fc gamma RIIA. In general, the described methodology involves the use of RNAi constructs that are targeted to an Fc gamma RIIA mRNA sequence.”
 

 
Title: RNAi Modulation of the Bcr-Abl Fusion Gene and Uses Thereof
 
Number: 20080293662
 
Filed: July 10, 2008
 
Lead Inventor: Philipp Hadwiger, Alnylam Pharmaceuticals
 
“The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference,” the patent application’s abstract states.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.